Clinical Trials Logo

Hepatobiliary Cancers clinical trials

View clinical trials related to Hepatobiliary Cancers.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06252753 Recruiting - Clinical trials for Hepatobiliary Cancers

Observational Study Protocol: LIVER-R

LIVER-R
Start date: December 20, 2023
Phase:
Study type: Observational

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence).